Defne Yarar Selected Research

MM-111

8/2013

Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Defne Yarar Research Topics

Disease

4	Neoplasms (Cancer) 01/2022 - 08/2013
2	Breast Neoplasms (Breast Cancer) 01/2017 - 08/2013
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2017
1	Lung Neoplasms (Lung Cancer) 01/2017
1	Ovarian Neoplasms (Ovarian Cancer) 01/2017
1	Disease Progression 01/2017
1	Carcinogenesis 01/2017
1	autosomal recessive 1 Spinocerebellar ataxia 11/2002

Drug/Important Bio-Agent (IBA)

1	Cancer VaccinesIBA 01/2022
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2022
1	Poly I-CIBA 01/2022
1	AntigensIBA 01/2022
1	seribantumabIBA 01/2017
1	histidine-rich proteinsIBA 01/2017
1	Hormones (Hormone)IBA 01/2017
1	Phosphatidylinositols (Phosphatidylinositol)IBA 01/2017
1	PlatinumIBA 01/2017
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	Messenger RNA (mRNA)IBA 01/2017
1	Phosphatidylinositol 3-Kinases (PI 3 Kinase)IBA 09/2015
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 08/2013
1	Neuregulin-1 (Neuregulin 1)IBA 08/2013
1	Lapatinib (GW572016)FDA Link 08/2013
1	Phosphotransferases (Kinase)IBA 08/2013
1	Trastuzumab (Herceptin)FDA Link 08/2013
1	MM-111IBA 08/2013
1	Drug CombinationsIBA 08/2013
1	Biomarkers (Surrogate Marker)IBA 08/2013
1	LigandsIBA 08/2013
1	ErbB Receptors (EGF Receptor)IBA 08/2013
1	Profilins (Profilin)IBA 11/2002
1	Proline (L-Proline)FDA Link 11/2002

Therapy/Procedure

3	Therapeutics 01/2017 - 08/2013